The content on this site is intended for healthcare professionals only
Dr Akhil Kapoor speaks to ecancer about his article on a study looking at the concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms.
He explains that this was a retrospective audit of a prospectively collected database of patients who had received ICI for advanced solid tumours in any line between August 2015 and November 2018 at Tata Memorial Hospital in Mumbai.
Dr Kapoor reports that patients who received antibiotics for more than 10 days had an OS of 2.8 months, compared with 8.8 months for patients who received less than 10 days of antibiotics.
He explains that this shows that a longer duration of antibiotics led to poorer outcomes.
You can read the article published in ecancermedicalscience here.
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Latest in PARP inhibitors and combination therapies for prostate cancer
